

**Charity Registration No. 1182637 (England and Wales)**

**Charity Registration No. SC049948 (Scotland)**

**Company Registration No. CE016951 (England and Wales)**

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**  
**OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION**  
**TRUSTEES' REPORT AND**  
**FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED**  
**31 DECEMBER 2024**

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION  
LEGAL AND ADMINISTRATIVE INFORMATION

---

Trustees	David Oxnam (Chair of Board of Trustees) Rachel Wilcox Sarah Curtis Dr Angela Polanco (Appointed 13 June 2025)
Chief Executive	Ashley Ball-Gamble
Charity number	1182637 (England and Wales) SC049948 (Scotland)
Company number	CE016951
Operating name	CCLG
Principal address	Century House 24 De Montfort Street Leicester LE1 7GB
Auditor	Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT
Bankers	HSBC Bank Plc 2-6 Gallowtree Gate Leicester LE1 1DA  Scottish Widows Bank Plc PO Box 12757 67 Morrison Street Edinburgh EH3 8YJ  CAF Bank Ltd 25 Kings Avenue Kings Hill Kent ME19 4JQ

---

# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION CONTENTS**

---

	<b>Page</b>
Trustees' report	1 - 12
Independent auditor's report	13 - 15
Statement of financial activities	16
Balance sheet	17
Statement of cash flows	18
Notes to the financial statements	19 - 33

---

# THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

---

The trustees of The Children's Cancer and Leukaemia Group, trading as CCLG: The Children & Young People's Cancer Association (CCLG), are pleased to present their annual report and financial statements for the year ended 31 December 2024.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity's governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

## **OBJECTIVES AND ACTIVITIES**

The objectives of CCLG as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.
2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.
3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.
4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

### **Expert clinical work**

CCLG is the UK and Ireland's professional association for all those involved in the treatment, care and research of children and young people (aged 0-25) with cancer. At the end of 2024, our membership had grown to more than 1,800 members. We also operate 'Teenagers and Young Adults with Cancer' (TYAC), a specific membership group for those working with young people aged 13-25 with a cancer diagnosis, which had over 470 members at the end of the year.

We bring together the experts in children and young people's cancer through our professional membership, creating a powerful national network driving progress. Together, we shape better treatment and care—developing guidelines, sharing expertise, offering advice, leading groundbreaking research, and creating essential resources and education for professionals. Our collective expertise sets the standard, advising, influencing, and advocating for excellence locally, nationally, and globally.

We carry out a wide range of activities to support our professional members, including:

- **Special Interest Groups and Member Networks:** Our Special Interest Groups (SIGs) bring together networks of members around specific cancer types, professions or disciplines, and key aspects of treatment and care. Our SIGs develop treatment guidelines, produce good practice guidance and resources to help professionals develop in their careers, develop and run educational opportunities for professionals, create new research projects, undertake quality improvement initiatives, provide networks for sharing best practice and new ideas, and lots more, with the ultimate aim of ensuring the best possible treatment and care for all children and young people.
- **Clinical treatment guidelines:** We develop national clinical treatment guidelines ensuring safe, consistent and standardised care for children with cancer. Where possible, children with cancer are

# THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

## OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

### TRUSTEES' REPORT (CONTINUED)

#### FOR THE YEAR ENDED 31 DECEMBER 2024

---

treated on clinical trials. However, the nature of research means that there will not always be open trials for some childhood cancers and using treatment guidelines is vital for ensuring equality of access to what is regarded by national experts as the best possible treatment currently available. CCLG members regularly review guidance and recommendations to cover all of the major children's cancers, including leukaemia. Our guidelines are written by national experts in the field of each tumour type, usually by members of the relevant CCLG Special Interest Group. Guidance and recommendations draw on evidence from international research and treatment protocols, and the aim is to ensure guidance is consistent with the standard of care internationally.

- **Education and professional development:** CCLG develops expert resources to support children and young people's cancer professionals in their careers, as well as providing professional education through meetings, conferences and webinars. We support the next generation of professionals including through our Paediatric Oncology Trainees Group and Early Career Researcher Network.
- **Our member website:** is a vital hub for professionals, providing a wealth of resources and educational opportunities, complemented by our online member community, allowing networking and good practice sharing opportunities beyond group meetings and events.
- **Professional voice for children, teenagers and young adults:** We advise governments and other bodies and ensure that we are represented on important groups or in consultations, for example in the area of NHS commissioning of children's cancer services or the development of NICE quality standards and guidance.

Our members are dedicated to ensuring that children and young people have a greater chance of survival and a better life after treatment.

#### Information and guidance

We support children and young people with cancer and their families in a variety of different ways:

- We provide trusted information and guidance for children and young people with cancer, their families, and everyone supporting them. Our expertise helps them navigate the challenges of cancer and its impact, offering reassurance and clarity when it's needed most.
- Our free booklets and factsheets, along with videos and our website, are a comprehensive resource for children and young people facing cancer, along with their families. Written by experts, including those with lived experience of children and young people's cancer, our information is reviewed regularly and accredited to the PIF Tick certification, so users can be assured it is trustworthy, and produced using strict quality criteria.
- Our free quarterly magazine, Contact, offers help, support and information for families of children, teenagers and young adults with cancer.
- Our online community provides a 'safe space' for parents of children with cancer to come together and share experiences, ask for advice, and, uniquely, ask expert questions of our professional membership.
- Our website is a comprehensive resource of childhood cancer information, providing a wide range of up-to-date expert information, personal stories and more.

#### Research

The incredible progress in treating cancer in children and young people is built on decades of dedicated research and clinical trials. Over the last 40 years, this research has transformed survival rates, with more than 80% of children now being cured. CCLG has been at the heart of this progress, driving research and collaboration to improve outcomes.

But there is still more to do. Some cancers remain difficult to treat, and many existing treatments cause long-term and life-changing side effects. We need more research to improve survival rates, develop kinder treatments, and ensure the best possible quality of life for children and young people after cancer.

At CCLG, we fund and support research across the entire cancer pathway—from diagnosis and treatment to patient experience and survivorship. We make sure research meets the real needs of children and young people with cancer, their families, and those who care for them. In 2022, we identified the top 10 priorities for childhood cancer research, shaped by the voices of children, young people, parents, and professionals.

# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024**

---

Collaboration is at the heart of what we do. We work with leading researchers and organisations to drive forward impactful studies, ensuring the best projects and brightest minds receive funding. We partner with other charities to maximise investment in research and use our expertise to support smaller charities in funding high-quality studies with real impact.

We lead the UK Children's and Teenage, Young Adult & Germ Cell Tumour Cancer Clinical Research Groups, shaping and overseeing clinical research across the UK. Our Special Interest Groups bring together experts to share knowledge and plan future research.

We create opportunities for discovery. We organise and support scientific meetings, ensuring vital research is shared, discussed, and developed. We empower our professional membership to be actively involved in shaping research. Our Early Career Research Network and dedicated funding for nurses, allied health professionals, and early-career researchers ensure the next generation of childhood cancer experts can continue to push boundaries and drive progress.

Our research strategy sets out our vision for the future of children and young people's cancer research—because every child deserves the best possible chance.

We work to share information about research, including results and outcomes, with the public, including through our popular research blog and a series of webinars on a variety of research topics.

Since 2017, CCLG has been a member of the Association of Medical Research Charities, demonstrating our commitment to funding high-quality, world class research and confirming the high standard of the processes we use to select and fund research.

## Policy and advocacy

We use our expertise and influence to make things better. By campaigning and advocating for children and young people with cancer, their families, and the professionals who support them, we're driving change where it matters most.

Working alongside politicians, governments, the NHS, and other organisations, we're pushing for progress and shaping a brighter future for young lives.

We combine our professional membership's expertise along with the voice of lived experience to develop position statements and policy ideas, shape campaigns, and respond to consultations from governments, the NHS, and other bodies about plans, policies, research or services for children and young people with cancer.

We also work in partnership with other organisations to ensure that children and young people's cancer has a strong, unified voice. We are a founding member of the Children and Young People's Cancer Coalition and our Chief Executive is the current Chair. We also contribute to wider policy work where it affects children and young people with cancer, including through our membership of Cancer 52 (the alliance for rare and less common cancers), the Association of Medical Research Charities, the Wales Cancer Alliance, and the One Cancer Voice coalition. Our Chief Executive was invited to be part of the Government's Children and Young People's Cancer Taskforce, working with the Department of Health and Social Care to drive forward improvements in the treatment and care of children, teenagers and young adults with cancer. This work was paused following the change in Government in May 2024, but re-started in early 2025 to support the development of the Government's forthcoming National Cancer Plan.

## Early diagnosis

Early diagnosis saves lives. Spotting cancer in children and young people early means better outcomes, fewer long-term effects, and the best chance of survival. That's why we're dedicated to making sure children and young people with symptoms of cancer get a diagnosis as quickly as possible.



# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024**

---

We raise awareness of the signs and symptoms, empowering families and communities to act sooner. For healthcare professionals, we provide tools and resources to support informed decisions about tests and scans. Together, we're working to ensure every child and young person gets the timely diagnosis they need.

We have information about the signs and symptoms of cancer in children and young people, and information and resources for healthcare professionals about diagnosing cancer in children and young people.

During the year we continued to focus on research to generate a new evidence base on how cancer presents in children and young people, as well as the routes to diagnosis, to inform a new national campaign, Child Cancer Smart, which will launch in 2025. Child Cancer Smart will raise awareness of the signs and symptoms of children's cancer, and provide tools for GPs and other healthcare professionals to support them to make timely and accurate referrals.

We measure our success in achieving our objectives in a number of ways:

- Analytics around our health information provision, including the number of information products distributed, website and social media analytics, and user-provided feedback, are used to measure our work in supporting patients and their families.
- The number of members and retention of members, attendance at and written feedback from education days, meetings and conferences, and informal member feedback, are some basic measures used to ascertain how we are supporting the community of professionals we serve through our professional association activities.
- The number of research projects funded and their value, and the outcome of research projects including peer-reviewed papers in scientific journals, and the number of projects that led to further funding from ourselves or another research funder.
- We have now begun developing our new strategic plan, set to launch in 2026. As part of this work, we will consider how we better measure and report on our impact.

## **ACHIEVEMENTS AND PERFORMANCE**

Around 1,800 children (aged 0-14) and a further 2,300 teenagers and young adults (aged 15-25) are diagnosed with cancer each year in the UK. Although overall five-year survival for cancer in children and young people is now over 80%, for some cancers there have not been such dramatic improvements in survival, and even where treatment is successful, many survivors have to contend with life-long and life-limiting side effects. We continue to work towards the four main goals set out in our strategic plan, launched in 2018, and the goals of the TYAC strategic plan, launched in 2019, as detailed below. Highlights of our achievements during the year are set out under each of these strategic goals.

### **Providing leadership and expertise for the treatment and care of children and young people with cancer**

As the UK and Ireland's professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children's cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. Highlights for 2024 include:

- Our Annual Conference continues to be the key professional event in children's, teenage and young adult cancer. This year we welcomed a record 600+ delegates to our two-day event, providing a unique opportunity for medical, healthcare and research professionals to come together and share news and discoveries.
- The conference featured our second annual Member Excellence Awards ceremony, celebrating the outstanding contribution of members to the work of CCLG and children and young people with cancer. The conference also showcased research, awarding prestigious CCLG Research Awards in a variety of categories recognising world-class, pioneering projects that are helping to break through boundaries and drive forward change in the treatment and care of young cancer patients.
- We held a variety of other educational and networking meetings, virtually and in-person, including a two-day course on neuroblastoma.

# THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

## OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

### TRUSTEES' REPORT (CONTINUED)

#### FOR THE YEAR ENDED 31 DECEMBER 2024

---

- We continued to produce and update a number of clinical treatment guidelines, ensuring standardised, high quality and evidence-based treatment for all children, particularly in diseases where there is currently no open clinical trial
- Our online member community, CCLG Connect, continued to go from strength to strength, providing a space for members to connect with each other, participate in group activities, share best-practice and research outputs, ask questions and disseminate useful resources.
- Our strategic partnership with Young Lives vs Cancer continued, providing benefits to both organisations. The Chief Nurse role at CCLG is funded by Young Lives vs Cancer, working to provide clinical and health system insight and intelligence to the latter and enhance support for nursing and allied health professionals within CCLG.
- In 2022, in partnership with Young Lives vs Cancer, the Ellen MacArthur Cancer Trust, and Teenage Cancer Trust, we commissioned a ground-breaking piece of research that will build a new evidence base looking at the psychosocial needs of young cancer patients and how the current system supports them. Dartington Service Design Lab, a charity which improves children's outcomes through research, systems thinking and co-design approaches, was commissioned as the research partner. This year, we published the findings of this research and as a result, the four charities launched the North Star, a vision informed by the report that sets out what needs to be accomplished.
  - Every child and young person facing cancer receives care that's tailored to them. They feel informed and in control, and along with their families can make knowledgeable decisions about their care and future. They feel empowered every step of the way, facing no gaps in support or barriers to access. They have everything they need from the beginning of their cancer journey, during treatment and for as long as they need it afterwards.

Following this, CCLG, Young Lives vs Cancer and the Ellen MacArthur Cancer Trust, formed a Collective Impact Collaborative, a collaboration between the charities that will continue to build on the findings of the research and work towards systemic change that will see the North Star come to fruition.

- We launched further modules of our e-learning programme to support the development of multiprofessionals in the early years of a career in children or teenage and young adult cancer services. The full set of nine units will form a foundation course called 'An introduction to cancer in a child, teenager and young adult' and the remaining units will all be available by the end of 2025. The aim is to improve options and access to foundation level learning in a timely way, in a format where learners can choose their own schedule of learning.
- We launched a revised career and education framework for long-term follow-up nurses, representing a significant review of competencies and career progression for highly specialised nursing working in this field. This sits alongside a number of significant career and education support resources and service development and delivery resources published by CCLG and widely used across NHS children and young people's cancer services.
- We launched two new member Special Interest Groups to bring together expert CCLG members with an interest in a particular area of work. Our Physical Activity and Exercise SIG focuses on the benefits of physical activity and exercise for young cancer patients and is working to develop evidence-based guidelines to improve participation in this area. Our 16-18 SIG is focused on the particular challenges faced by this age group as they make the transition for specialist children's cancer services into either teenage and young adult services or adult services.
- We continued to support a number of National Advisory Panels, groups of national experts in particular childhood cancers, to provide expert advice and treatment guidance for difficult-to-treat cases across the UK.
- We launched a number of new opportunities for our professional members to take up national leadership roles that both support their professional development as well as make contributions to key areas of CCLG activity. These include two nursing secondment roles to undertake reviews of key CCLG resources that are widely used by nursing teams across NHS services in the UK, and two Guideline Fellowships that will support our programme of developing clinical treatment guidelines and best practice guidelines for children and young people with cancer.

#### Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis and make appropriate onward referrals.



# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024**

---

Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently.

Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the UK are larger, at a more advanced stage and require more therapy than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2024:

- We continued our programme of research looking at how childhood cancer presents and the pathways to diagnosis, part of our Child Cancer Smart project. This will culminate in a large public awareness campaign, as well as the development of tools for professionals, which will launch in 2025. The aim of Child Cancer Smart is to raise awareness of the signs and symptoms of childhood cancer, and reduce the time taken for diagnosis.
- The Child Cancer Diagnosis Study, a research project funded by the National Institute for Health Research (NIHR) and CCLG, and jointly run by CCLG and The University of Nottingham, moved to the analysis stage, with the outcomes due to be published in 2025. This innovative, nationwide research will give us, for the first time, an accurate picture of the routes to diagnosis and where we can develop interventions to drive improvements.
- We published a paper calling for more research into population screening and targeted surveillance for children's and young people's cancer. The paper calls for prioritisation of research which investigates population screening and targeted surveillance for childhood cancer. Population screening would identify at-risk children, and targeted surveillance would identify changes and enable diagnosis as soon as they develop cancer. Earlier diagnosis could then improve survival rates and quality of life for young people with cancer.
- We played a leading role in running the second Teenage and Young Adult Cancer Awareness Month in April. This collaboration is an opportunity for charities and the young people we support to come together and raise awareness of the unique challenges facing this age group. The theme for this year was 'empowerment', focusing on supporting young people to take control of their healthcare. More than 20 charities took part in the collaboration.

## Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives. We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2024:

- We continued to provide free information booklets and leaflets to hospitals and directly to families during the year. A number of new publications were produced, and further existing publications were reviewed and revised.
- We produced four issues of our popular magazine, Contact. Feedback on the new format and design, launched in 2021, continues to be overwhelmingly positive, and Contact continues to support families across the UK and around the world.
- We continued our series of online 'research talks' aimed at parents of children with cancer (and the general public), which aim to explore the world of childhood cancer research in an accessible way, with each episode in the series featuring a talk from an expert speaker, as well as the opportunity for attendees to ask questions. Recordings of the webinars are made available on our YouTube channel for those unable to attend the live events.
- Our closed Facebook group for parents and carers of children with cancer, which allows members to seek advice and support from those with similar experiences, and, uniquely, 'ask the experts' through posting questions answered by our clinical membership community, continued to grow, reaching almost 1700 members.
- We successfully passed our annual reassessment for the Patient Information Forum (PIF) PIFTick accreditation for our health information. This quality standard is awarded following rigorous assessment of our information production processes, and demonstrates our commitment to reliable, expert, high-quality health information.

# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024**

---

## Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the children and young people's cancer community. Our Research Strategy outlines our plans to fund and support innovative world-class research into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements.

We fund research directly, and work with partner charities to support them to fund the best possible research, using our well-established research funding expertise, experience and infrastructure.

In total, between our own research funding and that of the partners we work with, 29 new research projects totalling around £3.4 million were funded in 2024. Grants awarded cover a wide range of cancer types, projects focusing on different parts of the cancer experience, and covering a range of different types of research.

- Our partnership with The Little Princess Trust continues to go from strength to strength. We support The Little Princess Trust to fund the best quality research, with a focus on finding better, kinder treatments. We provide specialist advice and expertise, as well as run and manage their research-funding programme on their behalf. This partnership helps to minimise duplication, and share expertise meaning that ultimately more money is spent directly on research. During the year, the Little Princess Trust awarded CCLG around £2.3 million to fund innovative new research proposals.
- We funded a series of biological studies pilot grants, in partnership with the VIVO Biobank, to provide pilot funding for early career researchers to undertake innovative projects that will advance our understanding of children's cancers.
- We funded a series of nursing and allied health professional research grants for the first time, supporting key professionals to get involved in research, explore research careers, and undertaken research projects that will focus on the care and experience of children and young people with cancer.
- Other grants awarded in the year include those for research projects focused on late effects, or the long-term consequences of cancer treatment, to improve our understanding of the impact of cancer once treatment ends, and how we can better support survivors.
- We announced a joint research funding call with the Bone Cancer Research Trust, to co-fund a number of research projects into primary bone cancers. This collaboration will allow us to make a significantly larger investment than either organisation would be able to do in isolation, leading to a bigger impact for those diagnosed with bone cancers.
- Following the closure of the National Cancer Research Institute (NCRI) in 2023, we continued to support the vital children, teenage and young adult work previously undertaken by the NCRI, providing a national strategic resource for the development of future clinical research.
- We continued to publish our research blog, aiming to make research understandable and accessible to all those in the childhood cancer community and beyond, including parents, professionals and the general public. The blog shares research concepts and specific projects in an accessible way, raising awareness of both the research we undertake and of cancer research more generally.
- We hosted another Research Discovery Day; to offer valuable insight into the research we fund to families and supporters. Among the attendees were parents of children diagnosed with cancer, survivors and CCLG fundraisers, who were able to hear experts talk about how they're working to improve the future for children with cancer.
- Following the publication of the Top 10 Priorities in Children's Cancer Research, the result of a James Lind Alliance Priority Setting Partnership funded by CCLG and The Little Princess Trust, we commissioned a 'mapping exercise' to understand the landscape of children's cancer research funding in the UK, collecting data on which of the Top 10 Priorities are being addressed and where there are gaps, to help us plan future research investment and ensure all of the priorities are addressed.
- During the year, we began developing our new Research Strategy, which will be published in 2025. We have been keen to ensure that a wide range of stakeholders had the opportunity to input into our strategy, bringing together clinicians, researchers and those with lived experience of children and young people's cancer, to ensure that our future research work meets the needs of all of those groups. As well as considering what research we will fund in the future, the strategy will explore how we can leverage our unique position as a professional association and charity, as well as our convening power and ability to build collaborations, to impact the entire children and young people's cancer research landscape.

# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024**

---

## Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families, and improve treatment and care for children and young people with cancer.

Our Special Named Fund programme continued to grow. After their cancer experiences, families sometimes consider setting up their own charity. For many, our Special Named Funds may be a great alternative. We support families to achieve their fundraising objectives, while taking away the administrative burden of setting up and running a charity. At the end of the year, there were approximately 104 Special Named Funds at CCLG (2023: 98), each raising funds to support research into a specific type of childhood cancer.

During the year, we rolled out a new internal fundraising strategy, which aims to ensure we are able to sustain our income growth and continue to deliver on our charitable objectives: funding research, supporting families and ensuring that all young patients receive the best possible treatment and care. The strategy includes investment in fundraising to develop our activity in key areas, as well as building on previous investments in data infrastructure which will allow us to make more strategic, data-driven decisions around fundraising activity.

We are hugely grateful to all those who chose to support CCLG, by making a donation, taking part in an event, or organising their own fundraiser during the year.

## Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public, we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into childhood cancer. We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials. Our supporters can also sign up to make regular donations. We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities. We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations.

Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies.

CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities.

Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

## FINANCIAL REVIEW

Transactions for the year ended 31 December 2024 fall into roughly the same categories as in previous years.

Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, funding from partner charities such as The Little Princess Trust to support research projects, and legacy income. We are grateful to Young Lives vs Cancer, Teenage Cancer Trust and The Little Princess Trust for their support of specific areas of our work.



# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**

## **OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION**

### **TRUSTEES' REPORT (CONTINUED)**

#### **FOR THE YEAR ENDED 31 DECEMBER 2024**

---

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants. Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity.

Our overall income decreased by £3,554,882, compared with the year ending December 2023. The majority of this was due to a reduction in research funding through our partnership with The Little Princess Trust, which was a planned reduction. The Trust has been investing reserves over the course of several years, as well as making strategic investments in specific research programmes (including the Experimental Cancer Medicines Network (ECMC)), and we now expect the income and expenditure through our partnership to remain broadly stable at this level in future years. We saw an increase in donations and legacies of £124,730 over last year, and a slight increase in investment income due to continued high interest rates.

CCLG has a number of restricted funds. Internal records are kept according to requirements for restriction, i.e. disease-specific donations for research into a specific type of cancer, or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

Expenditure decreased in 2024 by £2,233,875 compared to 2023. Again, this mainly reflects a reduction in research funded through our partnership with The Little Princess Trust compared to the previous year.

We ended the year with an overall deficit of £493,352. There was a surplus of unrestricted income of £36,724, compared with a deficit of £530,076 in restricted income and expenditure. This reflects our previous commitment to increasing our investment in research, and the fact the much of our restricted income is restricted to research into specific types of cancer, building over several years until there are sufficient funds available to invest in high-quality, impactful research projects.

#### Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. The COVID-19 pandemic followed by a period of global economic uncertainty and inflationary pressure has highlighted the importance of an appropriate reserves policy. It is important we continue to hold a level of reserves which can sustain our activity until we have a fuller picture of what the external environment, particularly in respect of fundraising and charitable giving, looks like in the medium-term.

We have plans in place to ensure CCLG is 'fit for the future' and our reserves policy will ensure we are able to meet those plans. At the end of the year, we have reviewed our reserves policy for CCLG and aim to hold a target level of free reserves (unrestricted funds less tangible fixed assets) of £250,000 - £500,000, which the trustees consider to be approximately three to six months of core expenditure, including staff salaries, accommodation costs and general running costs, based on the 2025 budget. This represents a change in our reserves policy from previous years, based on future income and expenditure projections, broadly stable (and more recently increasing) unrestricted income, and provides the flexibility to ensure that the charity can invest in charitable activities. The Trustees consider it prudent to balance the investment of reserves into charitable activity to meet the needs of our beneficiaries and fulfil the wishes of our donors and supporters. Having a reserves policy based on a range rather than a fixed figure, as previously, gives us the flexibility to be more responsive to appropriate opportunities for charitable investment.

Total reserves at 31 December 2024 were £2,795,200 (2023: £3,288,552) of which £2,368,518 (2023: £2,898,594) are restricted and £426,682 (2023: £389,958) are unrestricted. As at 31 December 2024 the charity's free reserves totalled £399,452 (2023: £358,954) which is comfortably within the range set out in the reserves policy. Given the current economic uncertainty, the trustees consider it prudent to balance the investment of reserves into our charitable activity whilst ensuring sufficient funds are available to ensure the charity is a 'going concern' and able to meet its commitments. The Trustees continue to keep the reserves policy under review to ensure that CCLG is 'fit for the future'.

# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024**

---

Our restricted reserves appear high, at £2,368,518 at the end of 2024. Much of our restricted fundraising income is raised by families, ring-fenced for research into specific types of childhood cancer. Research requires significant investment, and thus many of our funds grow over the course of several years before a large sum of money is awarded in the form of a research grant. Our restricted reserves comprise a large number of specific restricted funds which are ring-fenced to a specific purpose, and therefore cannot be used for general activities. Levels of funds are reviewed on a regular basis and spent on charitable activities as soon as sufficient funds are available. Our restricted reserves decreased at the end of 2024 compared with 2023, representing our commitment to increase our investment in research, and we expect to see a further decrease at the end of 2025 as we continue to support a wider range of research projects and explore collaborative opportunities with other funders.

## **Investment policy**

The Trustees previously reviewed our plans for investments to consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the ongoing uncertainty of the financial impact of the COVID-19 pandemic, and the cost-of-living crisis and high inflation, no further action has been taken on investments.

The high interest rates during the year have resulted in increased investment returns in the form of interest on money held in our bank accounts. Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

## **Risk Management**

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

## **FUTURE ACTIVITIES**

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives for children and young people with cancer, and their families, as the ultimate beneficiaries. As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and providing specialist advice to commissioners of healthcare services and others. The Executive continues to consider ways that CCLG can advance education and professional development, and share and guide best practice.

During 2024, we have been undertaking a number of strategic activities to lay strong foundations for the future of CCLG. These include:

- A review of our two membership bodies (CCLG and Teenagers and Young Adults with Cancer, TYAC) with a view to merging the two into a single, united association for the benefit of all children and young people with cancer. Following the review, carried out with a wide range of stakeholders, it was agreed there were many benefits to this approach, and in November we confirmed with the membership that we would proceed with merging the two memberships in early 2025.
- At the same time, we carried out a piece of work involving a wide range of stakeholders to understand the perceptions of CCLG, including our perceived strengths, weaknesses and potential opportunities for the organisation. Key themes included the value of our expertise, our strength as a convenor and leader of collaborations, our insights into the health system, and our bridge between professionals and patients and their families. The aim of this work was ultimately to build on our strengths, to improve our positioning and storytelling, and to raise awareness of CCLG and our work, with a long-term view of increasing support for and income to the charity.
- This work, along with the pending merger of the two professional bodies, resulted in a decision to rename the organisation and develop a new brand that would fulfil these aims. As a result, we began operating as CCLG: The Children & Young People's Cancer Association from March 2025.
- We continued with previously paused work on developing, building and launching a new website to accompany the new brand launch, and the make a more accessible online platform for patients and their



# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024**

---

families, as well as those seeking to support CCLG. The new website launched alongside the new brand in 2025.

Key planned activity for the next 12 months includes:

- Launching our new Research Strategy, which will include a focus on how we can have the most impact on the children and young people's cancer research landscape more broadly, by developing collaborations, supporting the research community, and ensuring that people with lived experience are at the heart of children and young people's cancer research.
- Launching a new 'lived experience' strategy, which sets out our commitments to involving people with lived experience of children and young people's cancer in our work, as well as providing a platform for people with lived experience to get involved in research and policy activity not just for CCLG but the wider sector.
- We will launch the first guidelines, clinical decision tools, and public awareness campaigns as part of our Child Cancer Smart programme of work, raising awareness of the signs and symptoms of cancer in children and young people, and equipping healthcare professionals to make quicker diagnoses.
- We will work to increase the range of health information content we provide, increasing the content available for teenagers and young adults with cancer, as well as providing content in alternative formats, including video and digital content, to better meet the needs of our intended users.
- We will increase our policy, advocacy and public affairs activity, working in collaboration with other organisations as needed, to ensure that our considerable expertise is used to influence decision-makers and other key stakeholders, inform governments, the NHS and other key organisations, and ultimately contributes to improvements for children and young people with cancer.
- We will continue to focus on building productive collaborations with other charities where we can share insights, work collectively, co-fund research projects, and otherwise have a bigger impact than we would be able to do working in isolation.

## **STRUCTURE, GOVERNANCE AND MANAGEMENT**

The Children's Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. In 2019, a new CIO (registration number 1182637) was formed, with the activities, assets and liabilities of the previous charity transferred to the CIO. The charity's governing instrument is the Constitution and the CIO was first registered in February 2019. In 2020, the CIO became registered with the Scottish Charity Regulator (registration number SC049948).

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for ensuring the charity meets its objectives, delivers on its strategy, has oversight of all activities of the charity, and managing the charity. There are a minimum of two and a maximum of twelve trustees.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate. Regard is given to the training and development needs of any trustees that may arise.

The trustees come from a range of professional backgrounds, and bring new skills and highly relevant experience. Trustees serving during the year were:

David Oxnam (Chair of Board of Trustees)

Gayle Routledge (resigned 13 June 2025)

Rachel Wilcox

David Hobin (resigned 31 March 2024)

Sarah Curtis

The Chief Executive is responsible for the day-to-day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional

# THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 12 to the accounts.

Key Management Personnel during the year were:

Ashley Ball-Gamble (Chief Executive)  
Claire Shinfield (Director of Engagement)  
Vicki Brunt (Head of Fundraising)  
Sarah Evans (Head of Research)  
Phil Welsh (Head of Communications)  
Jeanette Hawkins (Chief Nurse)  
Jo Stark (Chief Nurse)

## **STATEMENT OF TRUSTEES' RESPONSIBILITIES**

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities (Accounts and Reports) Regulations 2008, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- there is no relevant audit information of which the charity's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

DocuSigned by:  
  
29D0B5FD6D7043G.....  
David Oxnam  
Chair of the board of trustees  
Date: 18-09-2025

# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**

---

## **Opinion**

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the 'charity') for the year ended 31 December 2024 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2024 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

## **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

## **Other information**

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**

---

## **Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- the charity has not kept adequate and proper accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

## **Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement set out on page 12, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

## **Auditor's responsibilities for the audit of the financial statements**

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under these acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

## **Extent to which the audit was considered capable of detecting irregularities**

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charity.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, our procedures included the following:

- obtaining an understanding of the legal and regulatory framework applicable to the charity by considering the nature of the industry in which the charity operates and enquiring of management; and
- identifying the key laws and regulations considered to have a direct impact on the financial statements including the UK Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, UK Generally Accepted Accounting Practice and UK tax legislation; and
- assessing how the charity is complying with the applicable legal and regulatory framework by making further enquiries of management and observing the charity's control environment regarding compliance with regulations and fraud prevention; and
- assessing the susceptibility of the charity's financial statements to material misstatement, including how fraud might occur, by considering the effectiveness of the charity's accounting systems and controls and how these were monitored by management. Where the risk of material misstatement was considered to be higher in certain areas, further audit procedures were designed to address this increased risk; and



**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION  
INDEPENDENT AUDITOR'S REPORT (CONTINUED)  
TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**

---

- discussing amongst the engagement team how and where fraud might occur in the financial statements and any potential indicators of fraud.

**Audit response to risks of irregularities identified**

Our procedures to respond to risks identified included the following:

- performing audit work over revenue recognition including analytical procedures and substantive tests of detail of a sample of revenue transactions; and
- reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations; and
- enquiry of charity staff responsible for compliance to identify any instances of non-compliance with laws and regulations; and
- enquiry of management, those charged with governance and other relevant parties around actual and potential litigation claims; and
- reviewing minutes of meetings of those charged with governance; and
- performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness, evaluating the business rationale of significant transactions outside the normal course of business and reviewing accounting estimates for bias; and
- communicating identified laws and regulations and potential fraud risks to all engagement team members and assessing whether there are any indications of fraud or non-compliance with laws and regulations throughout the audit.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

**Use of our report**

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008, and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

  
**Newby Castleman LLP**

Chartered Accountants  
Statutory Auditor  
West Walk Building  
110 Regent Road  
Leicester  
LE1 7LT

19 September 2025

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.



**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION  
STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 DECEMBER 2024**

		<b>Unrestricted funds 2024 £</b>	<b>Restricted funds 2024 £</b>	<b>Total 2024 £</b>	<b>Total 2023 £</b>
	<b>Notes</b>				
<b>Income from:</b>					
Donations and legacies	<b>3</b>	953,823	627,879	1,581,702	1,456,972
Charitable activities	<b>4</b>	463,611	2,809,187	3,272,798	6,966,164
Investments	<b>5</b>	69,931	-	69,931	56,177
<b>Total</b>		<b>1,487,365</b>	<b>3,437,066</b>	<b>4,924,431</b>	<b>8,479,313</b>
<b>Expenditure on:</b>					
Raising funds	<b>6</b>	342,891	51,712	394,603	348,007
Charitable activities	<b>7</b>	1,103,627	3,919,553	5,023,180	7,303,651
<b>Total</b>		<b>1,446,518</b>	<b>3,971,265</b>	<b>5,417,783</b>	<b>7,651,658</b>
<b>Net incoming/(outgoing) resources before transfers</b>		<b>40,847</b>	<b>(534,199)</b>	<b>(493,352)</b>	<b>827,655</b>
Transfers between funds		(4,123)	4,123	-	-
<b>Net income/(expenditure) for the year/ Net movement in funds</b>		<b>36,724</b>	<b>(530,076)</b>	<b>(493,352)</b>	<b>827,655</b>
<b>Reconciliation of funds</b>					
Total funds brought forward		389,958	2,898,594	3,288,552	2,460,897
<b>Total funds carried forward</b>		<b>426,682</b>	<b>2,368,518</b>	<b>2,795,200</b>	<b>3,288,552</b>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION  
BALANCE SHEET  
AS AT 31 DECEMBER 2024**

	Notes	2024 £	£	2023 £	£
<b>Fixed assets</b>					
Tangible assets	14		27,230		31,004
<b>Current assets</b>					
Stocks	15	46,019		55,061	
Debtors	16	3,387,399		5,373,880	
Cash at bank and in hand		4,480,787		5,105,709	
		7,914,205		10,534,650	
<b>Liabilities</b>					
Creditors: amounts falling due within one year	17	(3,704,081)		(4,893,819)	
<b>Net current assets</b>			4,210,124		5,640,831
<b>Total assets less current liabilities</b>			4,237,354		5,671,835
<b>Creditors: amounts falling due after more than one year</b>	18		(1,442,154)		(2,383,283)
<b>Total net assets</b>			2,795,200		3,288,552
<b>The funds of the charity</b>					
Restricted funds	20	2,368,518		2,898,594	
Unrestricted funds	21	426,682		389,958	
<b>Total charity funds</b>			2,795,200		3,288,552

The financial statements were approved and authorised for issue by the board of trustees on 18-09-2025 and are signed on its behalf by:

DocuSigned by:

David Oxnam

29D0B5FD6D7849C:...

David Oxnam (Chair of Board of Trustees)

**Trustee**

The notes on pages 19 - 33 form part of these financial statements.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**  
**OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER**  
**ASSOCIATION**  
**STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

	Note	2024 £	£	2023 £	£
<b>Cash flows from operating activities</b>					
Cash (absorbed by)/generated from operations	26		(689,399)		1,026,714
<b>Investing activities</b>					
Purchase of tangible fixed assets		(5,454)		(2,592)	
Investment income received		69,931		56,177	
<b>Net cash generated from investing activities</b>			64,477		53,585
<b>Net cash used in financing activities</b>			-		-
<b>Net (decrease)/increase in cash and cash equivalents</b>			(624,922)		1,080,299
Cash and cash equivalents at beginning of year			5,105,709		4,025,410
<b>Cash and cash equivalents at end of year</b>			4,480,787		5,105,709

# **THE CHILDREN'S CANCER AND LEUKAEMIA GROUP OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION**

## **NOTES TO THE FINANCIAL STATEMENTS**

### **FOR THE YEAR ENDED 31 DECEMBER 2024**

---

#### **1 Accounting policies**

##### **Charity information**

The Children's Cancer and Leukaemia Group is governed by its Constitution.

##### **1.1 Basis of preparation**

The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

##### **1.2 Going concern**

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

##### **1.3 Charitable funds**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

##### **1.4 Income recognition**

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

- the charity has entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

# THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

## OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER ASSOCIATION

### NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 31 DECEMBER 2024

---

#### 1 Accounting policies

(Continued)

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

#### 1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Costs of raising funds includes costs incurred in seeking donations, grants and legacies, website costs and advertising.
- Expenditure on charitable activities includes research, educational activities and professional association activities to further the delivery of the objectives of the charity.

#### 1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

#### 1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Computer equipment, furniture and fixtures      5-10 years

#### 1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity's activities are valued at their service potential, which the charity considers to be the cost of the materials.

#### 1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

#### 1.10 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.



**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**1 Accounting policies**

**(Continued)**

**1.11 Employee benefits**

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

**1.12 Retirement benefits**

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

**2 Critical accounting estimates and judgements**

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

**Key sources of estimation uncertainty**

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:

**Allocation of support costs**

The allocation of support costs is sensitive to changes in the level of work undertaken on each activity by the charity. The allocation is reassessed annually and amended when necessary to reflect current estimates.

**3 Income from donations and legacies**

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Donations	626,417	627,879	1,254,296	622,960	703,031	1,325,991
Legacies	327,406	-	327,406	129,981	1,000	130,981
	<u>953,823</u>	<u>627,879</u>	<u>1,581,702</u>	<u>752,941</u>	<u>704,031</u>	<u>1,456,972</u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**  
**OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER**  
**ASSOCIATION**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**4 Income from charitable activities**

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Registration fees for meetings and other project expenditure	238,380	11,750	250,130	126,757	28,299	155,056
Member subscriptions and publication payments	152,428	-	152,428	153,279	-	153,279
Grant income for research and operations	72,803	2,701,486	2,774,289	72,359	6,506,385	6,578,744
CLIC Sargent chief nurse funding	-	95,951	95,951	-	79,085	79,085
	<u>463,611</u>	<u>2,809,187</u>	<u>3,272,798</u>	<u>352,395</u>	<u>6,613,769</u>	<u>6,966,164</u>

**5 Income from investments**

	Unrestricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Total 2023 £
Interest	69,931	69,931	56,177	56,177

**6 Expenditure on raising funds**

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
<u>Costs of raising funds</u>						
Fundraising platform fees	26,222	-	26,222	30,237	-	30,237
Website	2,293	14,934	17,227	3,567	9,474	13,041
Fundraising, marketing and publicity costs	138,031	36,778	174,809	110,813	26,750	137,563
Support costs (note 10)	176,345	-	176,345	167,166	-	167,166
	<u>342,891</u>	<u>51,712</u>	<u>394,603</u>	<u>311,783</u>	<u>36,224</u>	<u>348,007</u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**  
**OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER**  
**ASSOCIATION**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**7 Expenditure on charitable activities**

	Activities undertaken directly Note 8 £	Grant funding Note 9 £	Support Costs Note 10 £	Total 2024 £	Total 2023 £
Support for research	378,818	3,404,299	184,826	3,967,943	6,381,705
Information for patients and families	66,594	-	275,496	342,090	331,351
Improving treatment and care	418,206	-	294,941	713,147	590,595
	<u>863,618</u>	<u>3,404,299</u>	<u>755,263</u>	<u>5,023,180</u>	<u>7,303,651</u>
Unrestricted funds				1,103,627	950,732
Restricted funds				3,919,553	6,352,919
				<u>5,023,180</u>	<u>7,303,651</u>

**8 Expenditure on activities undertaken directly**

	Support for research £	Information for patients and families £	Improving treatment and care £	Total 2024 £	Total 2023 £
Staff costs	205,335	-	-	205,335	189,557
Other tumour specific expenditure	156,255	-	-	156,255	42,095
Contact magazine expenses	-	20,306	-	20,306	21,107
Other publication expenses	-	20,446	-	20,446	32,169
Website	17,228	25,842	25,842	68,912	52,163
Cost of meetings	-	-	344,837	344,837	266,303
Travel expenses	-	-	16,893	16,893	13,906
Membership support costs	-	-	24,094	24,094	11,767
Other expenses	-	-	6,540	6,540	6,782
	<u>378,818</u>	<u>66,594</u>	<u>418,206</u>	<u>863,618</u>	<u>635,849</u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**  
**OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER**  
**ASSOCIATION**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**9 Expenditure on grant funding**

	<b>Support for research £</b>	<b>Total 2024 £</b>	<b>Total 2023 £</b>
Grants to institutions:			
University of Birmingham	350,207	350,207	942,299
University of Surrey	112,216	112,216	-
Newcastle University	(474)	(474)	437,890
UCL Institute of Child Health	345,890	345,890	409,691
University of Sheffield	-	-	213,725
University of Nottingham	81,543	81,543	287,497
University of Bristol	61,069	61,069	321,339
Great Ormond Street	702,390	702,390	-
University of Southampton	-	-	222,463
University Hospital of Wales	(33,114)	(33,114)	-
University of Glasgow	216,831	216,831	124,806
University of York	252,682	252,682	559,734
University of Cambridge	493,268	493,268	248,355
Institute of Cancer Research	186,225	186,225	494,146
University of Leeds	61,556	61,556	96,468
University of Oxford	99,701	99,701	199,399
University College Cork	4,950	4,950	52,097
Swansea University	230,943	230,943	-
King's College London	74,458	74,458	-
The Open University	(94)	(94)	-
Brunel University London	-	-	352,568
Leeds Teaching Hospitals NHS Trust	-	-	104,631
University of Edinburgh	-	-	175,990
University of Sussex	-	-	249,969
University of Liverpool	-	-	170,788
Imperial College London	-	-	299,991
Sheffield Children's Foundation Trust	19,949	19,949	-
University Hospitals Bristol and Weston NHS Trust	19,743	19,743	-
University of East Anglia	124,360	124,360	-
	<u>3,404,299</u>	<u>3,404,299</u>	<u>5,963,846</u>

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

Negative amounts represent an underspend on grants previously made, returned to CCLG.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**  
**OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER**  
**ASSOCIATION**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**10 Expenditure on support costs**

	<b>Basis of allocation</b>	<b>2024</b>	<b>2023</b>
		<b>£</b>	<b>£</b>
Staff costs	*1	716,066	653,872
Depreciation & loss on disposal	*1	9,228	14,074
Occupancy expenses	*1	131,991	143,429
Postage	*1	15,896	14,253
Staff training	*1	8,571	10,205
Professional fees	*1 / *2	49,856	35,289
		<u>931,608</u>	<u>871,122</u>
Analysed between			
Raising funds		176,345	167,166
Charitable activities		755,263	703,956
		<u>931,608</u>	<u>871,122</u>

\*1 Support costs, excluding governance costs, have been allocated as follows:

<i>Cost of raising funds</i>	20% (2023 - 20%)
<i>Charitable activities</i>	
Support for research	20% (2023 - 20%)
Information for patients and families	30% (2023 - 30%)
Improving treatment and care	30% (2023 - 30%)

\*2 Professional fees include governance costs of £49,856 (2023 - £35,289). Governance costs have been allocated as follows:

<i>Charitable activities</i>	
Support for research	17% (2023 - 17%)
Information for patients and families	22% (2023 - 22%)
Improving treatment and care	61% (2023 - 61%)

The amount charged to the SOFA in respect of auditor's remuneration was:

- statutory audit £10,140 (2023 - £9,780)
- other services £1,382 (2023 - £989)

**11 Taxation**

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

**12 Trustees**

None of the trustees (or any persons connected with them) received any remuneration or benefits during the year.



**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**13 Employees**

The average monthly number of employees during the year was:

	<b>2024 Number</b>	<b>2023 Number</b>
Total	24	22

**Employment costs**

	<b>2024 £</b>	<b>2023 £</b>
Wages and salaries	769,767	709,013
Social security costs	75,889	68,378
Other pension costs	75,745	66,038
	<u>921,401</u>	<u>843,429</u>

The number of employees whose annual remuneration (excluding pension contributions) was more than £60,000 is as follows:

	<b>2024 Number</b>	<b>2023 Number</b>
£60,001 - £70,000	1	-
£70,001 - £80,000	-	1
£100,001 - £110,000	1	1
	<u>1</u>	<u>1</u>

**Remuneration of key management personnel**

The remuneration of key management personnel, is as follows.

	<b>2024 £</b>	<b>2023 £</b>
Aggregate compensation	<u>377,924</u>	<u>300,774</u>

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**14 Tangible fixed assets**

	<b>Computer equipment, furniture and fixtures £</b>	<b>Total £</b>
<b>Cost</b>		
At 1 January 2024	90,030	90,030
Additions	5,454	5,454
At 31 December 2024	95,484	95,484
<b>Depreciation and impairment</b>		
At 1 January 2024	59,026	59,026
Depreciation charged in the year	9,228	9,228
At 31 December 2024	68,254	68,254
<b>Carrying amount</b>		
At 31 December 2024	27,230	27,230
At 31 December 2023	31,004	31,004

**15 Stocks**

	<b>2024 £</b>	<b>2023 £</b>
Merchandise stock	23,412	31,790
Educational literature	22,607	23,271
	46,019	55,061

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**16 Debtors**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
<b>Amounts falling due within one year:</b>		
Trade debtors	25,298	19,656
Grant debtors	2,239,464	3,512,427
Rent deposit	18,600	16,200
Prepayments and accrued income	238,554	150,076
Accrued legacy income	283,500	138,500
	<u>2,805,416</u>	<u>3,836,859</u>
<b>Amounts falling due after more than one year:</b>		
	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Grant debtors	<u>581,983</u>	<u>1,537,021</u>
<b>Total debtors</b>	<u><u>3,387,399</u></u>	<u><u>5,373,880</u></u>

**17 Creditors: amounts falling due within one year**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Deferred income	32,241	19,559
Trade creditors	8,729	16,316
Grant creditors	3,622,339	4,821,058
Accruals	40,772	36,886
	<u>3,704,081</u>	<u>4,893,819</u>

Deferred income includes income received in respect of meetings to be held in the next financial year.

**18 Creditors: amounts falling due after more than one year**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Grant creditors	<u>1,442,154</u>	<u>2,383,283</u>

**19 Retirement benefit schemes****Defined contribution schemes**

The charity operates a defined contribution pension scheme for all qualifying employees.

The amount of contribution recognised in unrestricted expenditure was £75,746 (2023 - £66,038).

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**20 Restricted funds**

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

	<b>Balance at 1 January 2024</b>	<b>Movement in funds</b>			<b>Balance at 31 December 2024</b>
	<b>£</b>	<b>Income £</b>	<b>Expenditure £</b>	<b>Transfers £</b>	<b>£</b>
Tumour specific funds	1,605,293	1,006,365	(1,072,784)	-	1,538,874
CCLG Prize	364	-	-	-	364
General research fund	5,670	10,250	-	-	15,920
Adam Hay fund	11,262	-	-	-	11,262
CCLG Senior Members Group	7	-	-	-	7
PODC	6,850	915	(5,665)	-	2,100
POTG	2,156	10,170	(16,449)	4,123	-
The Little Princess Trust fund	6,200	2,314,140	(2,314,140)	-	6,200
Treatment Guidelines fund	614	-	-	-	614
TYAC Lisa Thaxter	21,632	-	(19,592)	-	2,040
Child Cancer Smart	37,786	-	(2,596)	-	35,190
PORT	420	-	-	-	420
CCLG Research Network					
Partner Charity	-	15,000	-	-	15,000
Neuroblastoma Nursing Group	1,500	-	-	-	1,500
PODC - Iraq Fund	9,694	850	(2,653)	-	7,891
Young Lives vs Cancer Chief					
Nurse Funding	2,332	79,376	(81,119)	-	589
Health Information	16,920	-	-	-	16,920
TYAC General Restricted	1,000	-	-	-	1,000
TYAC Research	66,496	-	-	-	66,496
Projects Restricted Fund	1,102,398	-	(456,267)	-	646,131
	<b>2,898,594</b>	<b>3,437,066</b>	<b>(3,971,265)</b>	<b>4,123</b>	<b>2,368,518</b>



**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**20 Restricted funds****(Continued)**

	<b>Balance at 1 January 2023</b>	<b>Movement in funds</b>		<b>Transfers</b>	<b>Balance at 31 December 2023</b>
	<b>£</b>	<b>Income £</b>	<b>Expenditure £</b>	<b>£</b>	<b>£</b>
Tumour specific funds	1,573,167	805,435	(773,309)	-	1,605,293
CCLG Prize	364	-	-	-	364
General research fund	3,180	2,490	-	-	5,670
Adam Hay fund	11,222	40	-	-	11,262
CCLG Senior Members Group	7	-	-	-	7
PODC	5,896	954	-	-	6,850
POTG	-	10,960	(8,804)	-	2,156
The Little Princess Trust fund	6,200	4,510,486	(4,510,486)	-	6,200
Treatment Guidelines fund	614	-	-	-	614
TYAC Lisa Thaxter	36,632	-	(15,000)	-	21,632
Child Cancer Smart	38,105	-	(319)	-	37,786
PORT	420	-	-	-	420
CCLG Research Network					
Partner Charity	-	652,188	(652,188)	-	-
Neuroblastoma Nursing Group	10,500	-	(9,000)	-	1,500
PODC - Iraq Fund	8,384	1,310	-	-	9,694
Young Lives vs Cancer Chief					
Nurse Funding	5,948	83,309	(86,925)	-	2,332
Health Information	16,920	12,300	(12,300)	-	16,920
TYAC General Restricted	1,000	-	-	-	1,000
TYAC Research	66,000	496	-	-	66,496
Projects Restricted Fund	185,378	1,237,832	(320,812)	-	1,102,398
	<u>1,969,937</u>	<u>7,317,800</u>	<u>(6,389,143)</u>	<u>-</u>	<u>2,898,594</u>

Transfers have been made into restricted funds from unrestricted funds to underwrite a cash deficit on a fund.

**Tumour specific funds**

Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

**CCLG Prize**

Represents income received from donors to fund the CCLG Prize.

**General research fund**

Represents income received from donors with a specific request that the funds are used for research purposes.

**Adam Hay fund**

This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

**CCLG Senior Members Group**

Represents income received from the Senior Members' Group to be used for their activities.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**20 Restricted funds**

**(Continued)**

**PODC**

Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

**POTG**

Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

**The Little Princess Trust fund**

Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

**Treatment Guidelines fund**

Represents a grant received for the development of rare endocrine tumour guidelines.

**TYAC Lisa Thaxter**

Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

**Child Cancer Smart**

Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

**PORT**

Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

**CCLG Research Network Partner Charity**

Represents income research from other charities to fund research projects.

**Neuroblastoma Nursing Group**

Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

**PODC - Iraq Fund**

Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

**Young Lives vs Cancer Chief Nurse Funding**

Funding for the Chief Nurse role and associated projects.

**Health Information**

Funds received to support the production of health information for patients and families.

**TYAC General Restricted**

Fundraising and donations to support work specifically for teenagers and young adults with cancer.

**TYAC Research**

Income restricted to support research projects into teenage and young adult cancer.

**Projects Restricted Funds**

Income restricted to support specific projects including work related to research.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP  
OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER  
ASSOCIATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**21 Unrestricted funds**

	Balance at 1 January 2024 £	Movement in funds			Balance at 31 December 2024 £
		Income £	Expenditure £	Transfers £	
General funds	389,958	1,487,365	(1,446,518)	(4,123)	426,682

  

	Balance at 1 January 2023 £	Movement in funds			Balance at 31 December 2023 £
		Income £	Expenditure £	Transfers £	
General funds	490,960	1,161,513	(1,262,515)	-	389,958

**22 Analysis of net assets between funds**

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
<b>Fund balances at 31 December 2024 are represented by:</b>			
Tangible assets	27,230	-	27,230
Current assets/(liabilities)	399,452	3,810,672	4,210,124
Long term liabilities	-	(1,442,154)	(1,442,154)
	426,682	2,368,518	2,795,200

  

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
<b>Fund balances at 31 December 2023 are represented by:</b>			
Tangible assets	31,004	-	31,004
Current assets/(liabilities)	358,954	5,281,877	5,640,831
Long term liabilities	-	(2,383,283)	(2,383,283)
	389,958	2,898,594	3,288,552

**23 Events after the reporting date**

The charity was notified of an additional legacy during the prior year. The timing and amount of the legacy income is uncertain as at the balance sheet date and therefore no income relating to this legacy has been recognised in these accounts.

**THE CHILDREN'S CANCER AND LEUKAEMIA GROUP**  
**OPERATING AS CCLG: THE CHILDREN AND YOUNG PEOPLE'S CANCER**  
**ASSOCIATION**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**24 Operating lease commitments**

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Within one year	39,096	18,397
Between two and five years	137,310	-
	<u>176,406</u>	<u>18,397</u>

Amounts recognised in the SOFA as an expense during the period in respect of operating lease arrangements are £37,471 (2023 - £36,530).

**25 Related party transactions**

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 12 to the financial statements.

**26 Cash generated from operations**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
(Deficit)/surplus for the year	(493,352)	827,655
Adjustments for:		
Investment income recognised in statement of financial activities	(69,931)	(56,177)
Depreciation and impairment of tangible fixed assets	9,228	14,074
Movements in working capital:		
Decrease/(increase) in stocks	9,042	(2,032)
Decrease/(increase) in debtors	1,986,481	(451,271)
(Decrease)/increase in creditors	(2,143,549)	675,006
Increase in deferred income	12,682	19,459
<b>Cash (absorbed by)/generated from operations</b>	<u>(689,399)</u>	<u>1,026,714</u>

**27 Analysis of changes in net funds**

During the year the charity had no borrowings or obligations under finance leases. The changes in net funds of the charity therefore solely comprise of cash and cash equivalents.